Skip to main content
. Author manuscript; available in PMC: 2019 Dec 1.
Published in final edited form as: Lancet Oncol. 2018 Nov 12;19(12):1641–1653. doi: 10.1016/S1470-2045(18)30576-X

Figure 4. Kaplan–Meier curves for progression-free survival and duration of response.

Figure 4.

Progression-free survival (A) and duration of response (B) from Part 2 (dose expansion phase; 3∙4 mg/kg dose) are shown. The median progression-free survival was 7·9 months and the median duration of response was not estimable. Tick marks indicate censored data.